★ WIDE MOAT STOCKS & COMPETITIVE ADVANTAGES ★
VOL. XCIV, NO. 247
Waters Corporation
WAT · New York Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Request update
Spot something outdated? Send a quick note and source so we can refresh this profile.
Overview
Waters Corporation is now a broader life science tools and diagnostics company after completing the February 9, 2026 Reverse Morris Trust combination with BD's Biosciences and Diagnostic Solutions businesses. Q1 2026 revenue was $1.267B, split roughly 47.9% Analytical Sciences, 18.3% Biosciences, 27.5% Advanced Diagnostics and 6.2% Materials Sciences. The legacy Waters moat remains rooted in LC/MS software workflows, regulated-method switching costs, chemistry consumables and global service contracts. The acquired BD portfolios add biosciences and diagnostics installed-base/reagent economics and clinical workflow exposure, but they also introduce integration risk, higher debt, transition-service dependencies and execution uncertainty around the expected $200M cost synergies and $290M revenue synergies.
Primary segment
Waters Analytical Sciences
Market structure
Oligopoly
Market share
—
HHI: —
Coverage
4 segments · 10 tags
Updated 2026-07-01
Segments
Waters Analytical Sciences
Liquid chromatography, mass spectrometry, precision chemistry consumables, informatics and related service for analytical laboratories
Revenue
47.9%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Waters Biosciences
Flow cytometry, immunology, cancer research, clinical diagnostics and multiomics tools from the acquired BD Biosciences portfolio
Revenue
18.3%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Waters Advanced Diagnostics
Diagnostic specimen collection, transport, infectious disease, cancer, healthcare-associated infection and clinical reagent systems
Revenue
27.5%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Waters Materials Sciences
Materials characterization instruments and related service, including thermal analysis, rheometry and calorimetry from TA Instruments
Revenue
6.2%
Structure
Oligopoly
Pricing
moderate
Share
—
Peers
Moat Claims
Waters Analytical Sciences
Liquid chromatography, mass spectrometry, precision chemistry consumables, informatics and related service for analytical laboratories
Revenue share uses Q1 2026 division revenue: Analytical Sciences $607M of total company revenue $1.267B. This division is the former core Waters business excluding the clinical business unit moved to Advanced Diagnostics.
Data Workflow Lockin
Demand
Data Workflow Lockin
Strength
Durability
Confidence
Evidence
Waters sells integrated LC/MS systems using common software platforms such as Empower and waters_connect, which embed methods, instrument control and data workflows in regulated labs.
Data Workflow Lockin moat: definition, examples, and stocks
Erosion risks
- Vendor-neutral informatics and open data standards reduce software switching friction
- Large labs standardize data workflows and multi-source instruments
- Capex weakness lengthens replacement cycles
Leading indicators
- Empower and waters_connect adoption
- Analytical Sciences instrument and chemistry growth
- Large pharma and QA/QC win rates
Counterarguments
- Waters software can interface with other manufacturers instruments, reducing exclusivity
- Thermo Fisher, Agilent and Danaher can bundle broader lab ecosystems
Design In Qualification
Demand
Design In Qualification
Strength
Durability
Confidence
Evidence
In regulated pharma and QA/QC labs, validated methods, training, software records and instrument qualification make vendor replacement costly and disruptive.
Design In Qualification moat: definition, examples, and stocks
Erosion risks
- Better method transfer tools reduce requalification burden
- Customers multi-source instruments for resilience and procurement leverage
- Competitor performance gains justify switching despite validation costs
Leading indicators
- Pharma and biopharma revenue mix
- Validation and compliance service attach rates
- Enterprise account retention
Counterarguments
- Regulated customers can switch when performance or throughput advantages are large enough
- CROs and multi-site enterprises often operate multi-vendor fleets
Service Field Network
Supply
Service Field Network
Strength
Durability
Confidence
Evidence
Waters field service, training, software maintenance and annual service contracts reduce downtime risk and reinforce installed-base retention.
Service Field Network moat: definition, examples, and stocks
Erosion risks
- Third-party service providers undercut OEM service plans
- Large labs internalize service capabilities
- Remote diagnostics reduce the value of onsite field networks
Leading indicators
- Service contract renewals and deferred revenue
- Service revenue growth versus installed base
- Field service response-time and satisfaction metrics
Counterarguments
- Third-party service is available for some mature instruments
- Customers can rebid service contracts during refresh cycles
Waters Biosciences
Flow cytometry, immunology, cancer research, clinical diagnostics and multiomics tools from the acquired BD Biosciences portfolio
Revenue share uses Q1 2026 owned-period revenue: Biosciences $232M of total company revenue $1.267B. The division was acquired from BD on February 9, 2026.
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
Flow cytometry and biosciences workflows typically pair instruments with reagents, assays, protocols and software, creating recurring consumables and method continuity around the installed base.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Integration disruption after the BD transaction
- Competitors win installed-base replacements during refresh cycles
- Customers standardize on alternative flow cytometry or multiomics platforms
Leading indicators
- Biosciences revenue growth versus pre-close trends
- Instrument placements and reagent pull-through
- Customer retention through the integration period
Counterarguments
- Waters is still proving ownership execution in this acquired portfolio
- Large rivals have entrenched life-science research ecosystems
Scope Economies
Supply
Scope Economies
Strength
Durability
Confidence
Evidence
The BD combination gives Waters a broader life-science workflow footprint spanning analytical chemistry, flow cytometry, multiomics and diagnostics, creating cross-sell potential but also integration risk.
Scope Economies moat: definition, examples, and stocks
Erosion risks
- Integration costs and customer disruption offset cross-sell benefits
- Sales organizations fail to coordinate across legacy Waters and BD portfolios
- Buyers resist bundling across research and diagnostic workflows
Leading indicators
- Reported revenue synergies
- Cross-sell wins between Analytical Sciences and Biosciences
- Customer churn in acquired accounts
Counterarguments
- Scope alone does not create lock-in if products are bought through separate budgets
- The largest competitors can offer equal or broader life-science portfolios
Waters Advanced Diagnostics
Diagnostic specimen collection, transport, infectious disease, cancer, healthcare-associated infection and clinical reagent systems
Revenue share uses Q1 2026 Advanced Diagnostics revenue: Diagnostic Solutions $288M plus the legacy Waters Clinical Business Unit $61M, or $349M of total company revenue $1.267B.
Compliance Advantage
Legal
Compliance Advantage
Strength
Durability
Confidence
Evidence
Clinical diagnostics are regulated, validated workflows where compliance, quality systems and continuity of approved assays can create switching friction.
Compliance Advantage moat: definition, examples, and stocks
Erosion risks
- Regulatory or reimbursement changes reduce profitability
- Hospitals consolidate purchasing and pressure prices
- Competing diagnostic platforms displace installed systems
Leading indicators
- Diagnostic Solutions revenue versus pre-close run rate
- Regulatory approvals and quality outcomes
- Reagent pull-through per installed system
Counterarguments
- Large diagnostic peers have broader installed bases and menu breadth
- Regulation raises barriers for all qualified incumbents, not only Waters
Installed Base Consumables
Demand
Installed Base Consumables
Strength
Durability
Confidence
Evidence
Diagnostic instruments and specimen-management workflows can generate recurring reagent, consumable and service demand once installed in clinical labs.
Installed Base Consumables moat: definition, examples, and stocks
Erosion risks
- Testing volumes shift to competing platforms
- Commodity specimen products face pricing pressure
- Integration disruption affects service and supply reliability
Leading indicators
- Reagent and consumables revenue growth
- Customer retention in diagnostic accounts
- Service levels and supply continuity during integration
Counterarguments
- Clinical labs can multi-source some consumables
- Installed-base economics depend on sustaining test menu relevance
Waters Materials Sciences
Materials characterization instruments and related service, including thermal analysis, rheometry and calorimetry from TA Instruments
Revenue share uses Q1 2026 Materials Sciences revenue of $79M, formerly known as the TA Division, divided by total company revenue of $1.267B.
Design In Qualification
Demand
Design In Qualification
Strength
Durability
Confidence
Evidence
TA instruments are embedded in materials development and production testing workflows; switching often requires method transfer, retraining and requalification of lab procedures.
Design In Qualification moat: definition, examples, and stocks
Erosion risks
- Lower-cost competitors and commoditization in mature categories
- Customer standardization on alternative materials-science platforms
- Rapid innovation resets brand preferences
Leading indicators
- Materials Sciences order growth
- Service attach and renewal rates
- Win/loss in thermal analysis and rheometry
Counterarguments
- Materials labs can be price-sensitive when performance differences are small
- Qualification burdens are typically lower than in regulated pharma QA/QC settings
Service Field Network
Supply
Service Field Network
Strength
Durability
Confidence
Evidence
TA service operations and installed-base support create recurring revenue and customer relationships in a cyclical capital equipment market.
Service Field Network moat: definition, examples, and stocks
Erosion risks
- Third-party service providers cover mature instruments
- Field engineer attrition and spare-parts constraints
- Industrial customers defer maintenance in downturns
Leading indicators
- TA service revenue as a percentage of Materials Sciences revenue
- Service renewal and attach rates
- Customer satisfaction and response-time metrics
Counterarguments
- Service economics depend on maintaining a sufficiently large installed base
- Third-party service can undercut OEM pricing for older instruments
Evidence
Products are sold as integrated instrument systems using common software platforms.
Integrated hardware and software support workflow switching costs in lab operations.
high-single-digit instrument growth and mid-teens chemistry growth within the Analytical Sciences Division
Current quarter evidence that the core analytical platform and chemistry franchise remained healthy after the BD transaction closed.
research and development, quality assurance and other laboratory applications
Anchors Waters use cases in QA/QC environments where method continuity matters.
Many of the Company's customers are in highly regulated industries.
Regulated end-markets raise switching friction through compliance and validation requirements.
79 direct sales offices and more than 4,200 field representatives worldwide.
Scale of field organization supports global service coverage.
Showing 5 of 17 sources.
Risks & Indicators
Erosion risks
- Vendor-neutral informatics and open data standards reduce software switching friction
- Large labs standardize data workflows and multi-source instruments
- Capex weakness lengthens replacement cycles
- Better method transfer tools reduce requalification burden
- Customers multi-source instruments for resilience and procurement leverage
- Competitor performance gains justify switching despite validation costs
Leading indicators
- Empower and waters_connect adoption
- Analytical Sciences instrument and chemistry growth
- Large pharma and QA/QC win rates
- Pharma and biopharma revenue mix
- Validation and compliance service attach rates
- Enterprise account retention
Research WAT elsewhere
Keep the research going
More Rankings & Systems
Quality Stocks
High quality stocks ranked by profitability, margins, free cash flow quality, durability, solvency, and accounting...
Stock rankingUndervalued Stocks
Undervalued stocks from the NA & Europe universe, ranked with a multi-measure value system and quality controls.
Stock rankingDividend Stocks
Dividend stocks ranked by payout yield, payout sustainability, dividend growth, quality, balance-sheet safety, risk...
Stock rankingDefensive Stocks
Defensive stocks ranked by low volatility, low beta, intermediate momentum, durable profitability, balance sheet...
Stock rankingMomentum Stocks
Momentum stocks ranked by total return momentum, relative momentum, trend confirmation, and risk-adjusted momentum...
Stock rankingConviction 10
A concentrated 10-stock strategy from the NA & Europe universe, ranked across quality, value, growth, momentum, and...
Curation & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.